PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population

Molecular Biology Reports

Volumn 38, Issue 2, 2011, Pages 1347-1351

  Herreros Villanueva, Marta ^a   Gomez Manero, Noemí ^a   Muñiz, Pilar ^b   García Girón, Carlos ^a   Coma Del Corral, Maria Jesús ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF BURGOS   (Spain)

Author keywords

BRAF; Cetuximab; Colorectal cancer; KRAS; PIK3CA

Indexed keywords

ADULT; AGED; ARTICLE; BRAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; SPAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SPAIN;

EID: 79951579573     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0236-6     Document Type: Article

References (32)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. MJ Waldner MF Neurath 2010 The molecular therapy of colorectal cancer Mol Aspects Med 31 2 171 178 1:CAS:528:DC%2BC3cXksFGqurY%3D 10.1016/j.mam.2010.02. 005 20171980
3. HJ Meulenbeld GJ Creemers 2007 First-line treatment strategies for elderly patients with metastatic colorectal cancer Drugs Aging 24 3 223 238 1:CAS:528:DC%2BD2sXlsVCnsLg%3D 10.2165/00002512-200724030-00004 17362050 (Pubitemid 46457025)
4. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
5. E Van Cutsem M Peeters S Siena, et al. 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 1658 1664 10.1200/JCO.2006.08.1620 17470858 (Pubitemid 46797944)
6. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 5 341 354 1:CAS:528:DC%2BD2MXjslertb0%3D 10.1038/nrc1609 15864276 (Pubitemid 40637826)
7. J Mendelsohn J Baselga 2006 Epidermal growth factor receptor targeting in cancer Semin Oncol 33 4 369 385 1:CAS:528:DC%2BD28XpsVersLk%3D 10.1053/j.seminoncol.2006.04.003 16890793 (Pubitemid 44142736)
8. J Downward 2003 Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 1 11 22 1:CAS:528:DC%2BD38XpvVertbo%3D 10.1038/nrc969 12509763 (Pubitemid 37328883)
9. M Malumbres M Barbacid 2003 RAS oncogenes: the first 30 years Nat Rev Cancer 3 6 459 465 1:CAS:528:DC%2BD3sXktFOnsbs%3D 10.1038/nrc1097 12778136 (Pubitemid 37328850)
10. S Schubbert K Shannon G Bollag 2007 Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 4 295 308 1:CAS:528:DC%2BD2sXjtlyhtLs%3D 10.1038/nrc2109 17384584 (Pubitemid 46480970)
11. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 1626 1634 1:CAS:528:DC%2BD1cXltlWhsrw%3D 10.1200/JCO.2007.14.7116 18316791
12. P Laurent-Puig A Cayre G Manceau, et al. 2009 Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 35 5924 5930 1:CAS:528: DC%2BC3cXhtVWis7c%3D 10.1200/JCO.2008.21.6796 19884556
13. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 5705 5712 1:CAS:528:DC%2BD1MXotFemsA%3D%3D 10.1200/JCO.2008.18.0786 19001320
14. S Benvenuti A Sartore-Bianchi F Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 6 2643 2648 1:CAS:528:DC%2BD2sXivV2ns7w%3D 10.1158/0008-5472.CAN- 06-4158 17363584 (Pubitemid 46548951)
15. W De Roock H Piessevaux J De Schutter, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 3 508 515 10.1093/annonc/mdm496 17998284 (Pubitemid 351325672)
16. F Di Fiore F Blanchard F Charbonnier, et al. 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 8 1166 1169 1:CAS:528:DC%2BD2sXkt1Gqsbs%3D 10.1038/sj.bjc.6603685 17375050 (Pubitemid 46625066)
17. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 3992 3995 1:CAS:528:DC%2BD28XjsFSlsb0%3D 10.1158/0008-5472.CAN-06-0191 16618717
18. JA Engelman J Luo LC Cantley 2006 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev 7 8 606 619 1:CAS:528:DC%2BD28XmvFCnu7Y%3D 10.1038/nrg1879 (Pubitemid 44100518)
19. B Karakas KE Bachman BH Park 2006 Mutation of the PIK3CA oncogene in human cancers Br J Cancer 94 4 455 459 1:CAS:528:DC%2BD28Xhs1ers70%3D 10.1038/sj.bjc.6602970 16449998 (Pubitemid 43289745)
20. BD Manning LC Cantley 2007 AKT/PKB signaling: navigating downstream Cell 129 7 1261 1274 1:CAS:528:DC%2BD2sXotV2hs7g%3D 10.1016/j.cell.2007.06.009 17604717 (Pubitemid 46962095)
21. Y Samuels VE Velculescu 2004 Oncogenic mutations of PIK3CA in human cancers Cell Cycle 3 10 1221 1224 1:CAS:528:DC%2BD2MXhtFChu7rM 15467468 (Pubitemid 40268595)
22. T Ikenoue F Kanai Y Hikiba, et al. 2005 Functional analysis of PIK3CA gene mutations in human colorectal cancer Cancer Res 65 11 4562 4567 1:CAS:528:DC%2BD2MXks1Oht7c%3D 10.1158/0008-5472.CAN-04-4114 15930273 (Pubitemid 40740791)
23. S Ogino K Nosho GJ Kirkner, et al. 2009 PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 9 1477 1484 1:CAS:528:DC%2BD1MXksF2hsL4%3D 10.1200/JCO.2008.18.6544 19237633
24. F Perrone A Lampis M Orsenigo, et al. 2009 PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 1 84 90 1:STN:280:DC%2BD1M%2Fns1yktw%3D%3D 10.1093/annonc/mdn541 18669866
25. CR Newton A Graham LE Heptinstall, et al. 1989 Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 7 2503 2516 1:CAS:528:DyaL1MXktFyktbs%3D 10.1093/nar/17.7.2503 2785681 (Pubitemid 19103235)
26. N Thelwell S Millington A Solinas J Booth T Brown 2000 Mode of action and application of scorpion primers to mutation detection Nucleic Acids Res 28 19 3752 3761 1:CAS:528:DC%2BD3cXntlKmurk%3D 10.1093/nar/28.19.3752 11000267
27. D Whitcombe J Theaker SP Guy T Brown S Little 1999 Detection of PCR products using self-probing amplicons and fluorescence Nat Biotechnol 17 8 804 807 1:CAS:528:DyaK1MXmtFahsr0%3D 10.1038/11751 10429248 (Pubitemid 29365111)
28. S Benlloch A Paya C Alenda, et al. 2006 Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology J Mol Diagn 8 5 540 543 1:CAS:528:DC%2BD28Xhtlagu7zM 10.2353/jmoldx.2006.060070 17065421 (Pubitemid 44774151)
29. RE Board NJ Thelwell PF Ravetto, et al. 2008 Multiplexed assays for detection of mutations in PIK3CA Clin Chem 54 4 757 760 1:CAS:528: DC%2BD1cXkt1Cjsr4%3D 10.1373/clinchem.2007.098376 18375489 (Pubitemid 351573719)
30. AI Ekstrand M Jonsson A Lindblom A Borg M Nilbert 2010 Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer Fam Cancer 9 2 125 129 1:CAS:528:DC%2BC3cXmtVyku7o%3D 10.1007/s10689-009-9293-1 19731079
31. S Velho C Oliveira A Ferreira, et al. 2005 The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 11 1649 1654 1:CAS:528:DC%2BD2MXmsVCmu7s%3D 10.1016/j.ejca.2005.04.022 15994075 (Pubitemid 40981849)
32. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790-799